350 related articles for article (PubMed ID: 27732933)
1. CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma.
Thangavadivel S; Zelle-Rieser C; Olivier A; Postert B; Untergasser G; Kern J; Brunner A; Gunsilius E; Biedermann R; Hajek R; Pour L; Willenbacher W; Greil R; Jöhrer K
Oncotarget; 2016 Nov; 7(48):78605-78618. PubMed ID: 27732933
[TBL] [Abstract][Full Text] [Related]
2. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
[TBL] [Abstract][Full Text] [Related]
3. CCR10 activation stimulates the invasion and migration of breast cancer cells through the ERK1/2/MMP-7 signaling pathway.
Lin HY; Sun SM; Lu XF; Chen PY; Chen CF; Liang WQ; Peng CY
Int Immunopharmacol; 2017 Oct; 51():124-130. PubMed ID: 28830025
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors.
Tagoug I; Jordheim LP; Herveau S; Matera EL; Huber AL; Chettab K; Manié S; Dumontet C
Clin Cancer Res; 2013 Jul; 19(13):3556-66. PubMed ID: 23674497
[TBL] [Abstract][Full Text] [Related]
5. Proteasome inhibition correlates with intracellular bortezomib concentrations but not with antiproliferative effects after bolus treatment in myeloma cell lines.
Dettmer S; Theile D; Schäfer J; Seckinger A; Burhenne J; Weiss J
Naunyn Schmiedebergs Arch Pharmacol; 2016 Oct; 389(10):1091-101. PubMed ID: 27422413
[TBL] [Abstract][Full Text] [Related]
6. CCR10 and CCL27 are overexpressed in cutaneous squamous cell carcinoma.
Kai H; Kadono T; Kakinuma T; Tomita M; Ohmatsu H; Asano Y; Tada Y; Sugaya M; Sato S
Pathol Res Pract; 2011 Jan; 207(1):43-8. PubMed ID: 21144674
[TBL] [Abstract][Full Text] [Related]
7. Oral proteasome inhibitor with strong preclinical efficacy in myeloma models.
Park J; Park E; Jung CK; Kang SW; Kim BG; Jung Y; Kim TH; Lim JY; Lee SE; Min CK; Won KA
BMC Cancer; 2016 Mar; 16():247. PubMed ID: 27012957
[TBL] [Abstract][Full Text] [Related]
8. Non-lethal proteasome inhibition activates pro-tumorigenic pathways in multiple myeloma cells.
Skorda A; Sklirou AD; Sakellaropoulos T; Gianniou DD; Kastritis E; Terpos E; Tsitsilonis OE; Florea BI; Overkleeft HS; Dimopoulos MA; Alexopoulos LG; Trougakos IP
J Cell Mol Med; 2019 Dec; 23(12):8010-8018. PubMed ID: 31568628
[TBL] [Abstract][Full Text] [Related]
9. ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF-κB in multiple myeloma.
Jiang J; Sun Y; Xu J; Xu T; Xu Z; Liu P
Cancer Med; 2020 Oct; 9(19):7244-7252. PubMed ID: 32780537
[TBL] [Abstract][Full Text] [Related]
10. Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance.
Song Y; Li S; Ray A; Das DS; Qi J; Samur MK; Tai YT; Munshi N; Carrasco RD; Chauhan D; Anderson KC
Oncogene; 2017 Oct; 36(40):5631-5638. PubMed ID: 28581522
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
Kim A; Seong KM; Kang HJ; Park S; Lee SS
Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
[TBL] [Abstract][Full Text] [Related]
12. Endothelin-1 (ET-1) induces resistance to bortezomib in human multiple myeloma cells via a pathway involving the ETB receptor and upregulation of proteasomal activity.
Vaiou M; Pangou E; Liakos P; Sakellaridis N; Vassilopoulos G; Dimas K; Papandreou C
J Cancer Res Clin Oncol; 2016 Oct; 142(10):2141-58. PubMed ID: 27530445
[TBL] [Abstract][Full Text] [Related]
13. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
[TBL] [Abstract][Full Text] [Related]
14. Molecular chaperone GRP78 enhances aggresome delivery to autophagosomes to promote drug resistance in multiple myeloma.
Abdel Malek MA; Jagannathan S; Malek E; Sayed DM; Elgammal SA; Abd El-Azeem HG; Thabet NM; Driscoll JJ
Oncotarget; 2015 Feb; 6(5):3098-110. PubMed ID: 25605012
[TBL] [Abstract][Full Text] [Related]
15. Targeting NSD2-mediated SRC-3 liquid-liquid phase separation sensitizes bortezomib treatment in multiple myeloma.
Liu J; Xie Y; Guo J; Li X; Wang J; Jiang H; Peng Z; Wang J; Wang S; Li Q; Ye L; Zhong Y; Zhang Q; Liu X; Lonard DM; Wang J; O'Malley BW; Liu Z
Nat Commun; 2021 Feb; 12(1):1022. PubMed ID: 33589584
[TBL] [Abstract][Full Text] [Related]
16. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
[TBL] [Abstract][Full Text] [Related]
17. Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling.
Zhang XD; Baladandayuthapani V; Lin H; Mulligan G; Li B; Esseltine DW; Qi L; Xu J; Hunziker W; Barlogie B; Usmani SZ; Zhang Q; Crowley J; Hoering A; Shah JJ; Weber DM; Manasanch EE; Thomas SK; Li BZ; Wang HH; Zhang J; Kuiatse I; Tang JL; Wang H; He J; Yang J; Milan E; Cenci S; Ma WC; Wang ZQ; Davis RE; Yang L; Orlowski RZ
Cancer Cell; 2016 May; 29(5):639-652. PubMed ID: 27132469
[TBL] [Abstract][Full Text] [Related]
18. Exosome-Transmitted
Xu H; Han H; Song S; Yi N; Qian C; Qiu Y; Zhou W; Hong Y; Zhuang W; Li Z; Li B; Zhuang W
Clin Cancer Res; 2019 Mar; 25(6):1923-1935. PubMed ID: 30610101
[TBL] [Abstract][Full Text] [Related]
19. High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib.
Malek E; Driscoll JJ
Oncotarget; 2016 Jun; 7(25):38523-38538. PubMed ID: 27229530
[TBL] [Abstract][Full Text] [Related]
20. [Mechanism of action and determinants of sensitivity to the proteasome inhibitor bortezomib in multiple myeloma therapy].
Ri M
Rinsho Ketsueki; 2016 May; 57(5):537-45. PubMed ID: 27263777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]